AngioDynamics, Inc. (NASDAQ:ANGO) Position Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 34.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 104,861 shares of the medical instruments supplier’s stock after acquiring an additional 26,761 shares during the quarter. JPMorgan Chase & Co. owned 0.29% of AngioDynamics worth $1,709,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC purchased a new position in shares of AngioDynamics during the third quarter worth approximately $143,000. Acrospire Investment Management LLC raised its stake in shares of AngioDynamics by 3.7% during the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 317 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in shares of AngioDynamics by 54.9% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 11,000 shares of the medical instruments supplier’s stock worth $178,000 after acquiring an additional 3,900 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of AngioDynamics by 49.3% during the second quarter. BNP Paribas Arbitrage SA now owns 14,135 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 4,668 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in shares of AngioDynamics by 7.2% during the second quarter. Arizona State Retirement System now owns 17,796 shares of the medical instruments supplier’s stock worth $288,000 after acquiring an additional 1,200 shares in the last quarter. 94.83% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AngioDynamics, Inc. (NASDAQ ANGO) traded up $0.29 during midday trading on Thursday, hitting $17.70. 381,066 shares of the company traded hands, compared to its average volume of 317,344. The company has a current ratio of 2.56, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. AngioDynamics, Inc. has a 12 month low of $14.80 and a 12 month high of $18.85. The stock has a market capitalization of $633.86, a P/E ratio of -84.28, a price-to-earnings-growth ratio of 1.60 and a beta of 1.04.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. AngioDynamics had a negative net margin of 2.27% and a positive return on equity of 4.63%. The company had revenue of $86.70 million for the quarter, compared to the consensus estimate of $88.15 million. During the same period in the previous year, the firm earned $0.19 earnings per share. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. equities analysts predict that AngioDynamics, Inc. will post 0.72 EPS for the current year.

ANGO has been the topic of several research reports. BidaskClub downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Craig Hallum downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Zacks Investment Research raised shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Monday, January 22nd. TheStreet downgraded shares of AngioDynamics from a “b-” rating to a “c” rating in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity reissued a “hold” rating and set a $17.00 price target on shares of AngioDynamics in a research note on Sunday, October 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $18.60.

WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/01/jpmorgan-chase-co-grows-position-in-angiodynamics-inc-ango.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply